Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

M Luengo, C Picado, L Del Rio, N Guañabens, J M Montserrat, J Setoain

Servei de Pneumologia, Hospital Clinic, Facultat de Medicina, Barcelona, Spain.

BACKGROUND: Reduced bone mass predisposes patients to the development of vertebral fractures. Measurement of bone mass by non-invasive methods is used to detect patients with involutional osteoporosis at risk from fractures. These methods have not been assessed in patients with steroid dependent osteoporosis. The objective of this study was to assess the value of a predictive fracture threshold value of bone density in patients with steroid dependent asthma. METHODS: Three groups of patients were studied. Group 1 (67 patients) had steroid dependent asthma (mean daily dose of prednisone 11.7 mg) and no vertebral fractures, group 2 (32 patients) had steroid dependent asthma (mean daily dose of prednisone 12 mg) and vertebral fractures, and group 3 (55 patients) were not taking steroids but had involutional osteoporosis and a recent non-traumatic vertebral fracture. Bone mineral density was measured by dual photon absorptiometry and vertebral fractures by radiography of the lumbar spine. A fracture threshold was determined in the two groups with fractures as the 90th percentile of the mean bone mineral density measured in the lumbar spine. RESULTS: Bone mineral density was significantly higher in the steroid dependent group with fractures (group 2) than in group 3 patients, who had involutional osteoporosis and fractures (0.946 (0.18) g/cm2 v 0.830 (0.16) g/cm2). The fracture threshold value was therefore higher for patients with steroid related vertebral fractures (group 2, 1.173 g/cm2) than for those with involutional osteoporosis (group 3, 0.979 g/cm2). Vertebral fractures were more likely to occur in steroid dependent asthmatic patients with bone density above the fracture threshold value (obtained from subjects with involutional osteoporosis) than in subjects in group 3 (34% v 9%). CONCLUSION: Vertebral fractures occur in patients treated with steroids in the presence of higher bone mineral density than is the case with patients with involutional osteoporosis. The findings suggests that the assessment of the efficacy of preventive treatment requires measurement of bone mineral density and radiology.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.

S J Gallacher, J A Fenner, K Anderson, B B Adamson, S W Banham, and I T Boyle
Thorax 1992 47: 207-208. [PDF]

This article has been cited by other articles:

• Syed, M.I., Patel, N.A., Jan, S., Shaikh, A., Grunden, B., Morar, K. (2006). Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis.. Am. J. Neuroradiol. 27: 1938-1943 [Abstract] [Full Text]  
• Heffernan, M. P., Saag, K. G., Robinson, J. K., Callen, J. P. (2006). Prevention of Osteoporosis Associated With Chronic Glucocorticoid Therapy. JAMA 295: 1300-1303 [Full Text]  
• Prather, H., Van Dillen, L., Metzler, J. P., Riew, K. D., Gilula, L. A. (2006). Prospective Measurement of Function and Pain in Patients with Non-Neoplastic Compression Fractures Treated with Vertebroplasty. JBJS 88: 334-341 [Abstract] [Full Text]  
• Liu, R. H., Albrecht, J., Werth, V. P. (2006). Cross-sectional Study of Bisphosphonate Use in Dermatology Patients Receiving Long-term Oral Corticosteroid Therapy. Arch Dermatol 142: 37-41 [Abstract] [Full Text]  
• Summey, B. T., Yosipovitch, G. (2006). Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update. Arch Dermatol 142: 82-90 [Abstract] [Full Text]  
• Mok, C C, Mak, A, Ma, K M (2005). Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14: 106-112 [Abstract]  
• Campbell, I A, Douglas, J G, Francis, R M, Prescott, R J, Reid, D M (2004). Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 59: 761-768 [Abstract] [Full Text]  
• Orstavik, R E, Haugeberg, G, Uhlig, T, Mowinckel, P, Kvien, T K, Falch, J A, Halse, J I (2004). Quantitative ultrasound and bone mineral density: discriminatory ability in patients with rheumatoid arthritis and controls with and without vertebral deformities. Ann Rheum Dis 63: 945-951 [Abstract] [Full Text]  
• Gluck, O., Colice, G. (2004). Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases. Chest 125: 1859-1876 [Abstract] [Full Text]  
• O'Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., Weinstein, R. S. (2004). Glucocorticoids Act Directly on Osteoblasts and Osteocytes to Induce Their Apoptosis and Reduce Bone Formation and Strength. Endocrinology 145: 1835-1841 [Abstract] [Full Text]  
• Dolan, A L, Koshy, E, Waker, M, Goble, C M (2004). Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients. Ann Rheum Dis 63: 183-186 [Abstract] [Full Text]  
• Adler, R. A., Hochberg, M. C. (2003). Suggested Guidelines for Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163: 2619-2624 [Abstract] [Full Text]  
• Ionescu, A.A., Schoon, E. (2003). Osteoporosis in chronic obstructive pulmonary disease. Eur Respir J 22: 64s-75s [Abstract] [Full Text]  
• Ringe, J. D., Dorst, A., Faber, H., Ibach, K., Preuss, J. (2003). Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology (Oxford) 42: 743-749 [Abstract] [Full Text]  
• Chantler, I W, Davie, M W J, Evans, S F, Rees, J S (2003). Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 62: 350-352 [Abstract] [Full Text]  
• Yeap, S. S., Hosking, D. J. (2002). Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford) 41: 1088-1094 [Abstract] [Full Text]  
• Walsh, L. J., Lewis, S. A., Wong, C. A., Cooper, S., Oborne, J., Cawte, S. A., Harrison, T., Green, D. J., Pringle, M., Hubbard, R., Tattersfield, A. E. (2002). The Impact of Oral Corticosteroid Use on Bone Mineral Density and Vertebral Fracture. Am. J. Respir. Crit. Care Med. 166: 691-695 [Abstract] [Full Text]  
• van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., Cooper, C. (2000). Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39: 1383-1389 [Abstract] [Full Text]  
• Naganathan, V., Jones, G., Nash, P., Nicholson, G., Eisman, J., Sambrook, P. N. (2000). Vertebral Fracture Risk With Long-term Corticosteroid Therapy: Prevalence and Relation to Age, Bone Density, and Corticosteroid Use. Arch Intern Med 160: 2917-2922 [Abstract] [Full Text]  
• Evans, S F, Davie, M W J (2000). Vertebral fractures and bone mineral density in idiopathic, secondary and corticosteroid associated osteoporosis in men. Ann Rheum Dis 59: 269-275 [Abstract] [Full Text]  
• Reid, I. R. (1999). Glucocorticoid Osteoporosis: Reid IR Glucocorticoid osteoporosis J Intensive Care Med 1999, 14231-242. J Intensive Care Med 14: 231-242  
• COMPSTON, J E (1999). Management of bone disease in patients on long term glucocorticoid therapy. Gut 44: 770-772 [Full Text]  
• Roux, C., Oriente, P., Laan, R., Hughes, R. A., Ittner, J., Goemaere, S., Di Munno, O., Pouillès, J. M., Horlait, S., Cortet, B. (1998). Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss. J. Clin. Endocrinol. Metab. 83: 1128-1133 [Abstract] [Full Text]  
• (1996). Corticosteroid-induced osteoporosis. DTB 34: 84-86 [Abstract] [Full Text]  
• Walsh, L J, Wong, C A, Pringle, M, Tattersfield, A E (1996). Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313: 344-346 [Abstract] [Full Text]  
• Reid, I. R., Wattie, D. J., Evans, M. C., Stapleton, J. P. (1996). Testosterone Therapy in Glucocorticoid-Treated Men. Arch Intern Med 156: 1173-1177 [Abstract]